Robot-Only lung surgery may cut costs without sacrificing safety
NCT ID NCT06348030
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two ways of performing robotic lung surgery for early-stage non-small cell lung cancer. In one method, the surgeon controls all tools from a console (totally robotic). In the other, a bedside assistant helps with handheld staplers. The trial will measure costs, operating time, hospital stay, and complications in 120 patients. The goal is to see if the fully robotic approach is more efficient and cost-effective.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Robotic surgical devices (Vessel Sealer Extend, SureForm stapler, Signia stapler)
- What this could lead to
- If successful, this could show that totally robotic lung surgery is as safe and less costly than surgeon-assisted methods, potentially becoming the new standard.
- What could go wrong
- This is a small, early-stage trial (120 people) comparing surgical techniques, not testing a new drug or cure. Results may not apply to all patients or hospitals.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 120 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2026
An estimate. Start dates often move.
- Expected to finish
-
Apr 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 120 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age between 18 and 120 years at time of consent * Ability to speak and understand English * Clinical stage I, II or IIIa NSCLC * Candidate for RTS, as determined by the operating surgeon Exclusion Criteria: * Anticoagulation with inability to cease anticoagulant therapy prior to surgery * Incurable coagulopathy * Systemic vascular disease or vasculitis * Not a candidate for RTS
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Lung cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
St. Joseph's Healthcare Hamilton
Hamilton, Ontario, L8N 4A6, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Two-Drug combo targets stubborn KRAS lung cancer
- Smaller chest drain may speed recovery after lung cancer surgery
- Gut bacteria may hold clues to why some cancer treatments work better
- Can an Anti-Fibrotic drug shield lungs from radiation after immunotherapy?
- Breath-Tracking sensor aims to sharpen lung cancer scans
- App aims to catch a hidden radiotherapy side effect